Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial.
Sharp A, Cornforth C, Jackson R, Harrold J, Turner MA, Kenny LC, Baker PN, Johnstone ED, Khalil A, von Dadelszen P, Papageorghiou AT, Alfirevic Z; STRIDER group. Sharp A, et al. Among authors: jackson r. Lancet Child Adolesc Health. 2018 Feb;2(2):93-102. doi: 10.1016/S2352-4642(17)30173-6. Epub 2017 Dec 7. Lancet Child Adolesc Health. 2018. PMID: 30169244 Free article. Clinical Trial.
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP. Middleton G, et al. Among authors: jackson r. Lancet Oncol. 2017 Apr;18(4):486-499. doi: 10.1016/S1470-2045(17)30084-0. Epub 2017 Mar 2. Lancet Oncol. 2017. PMID: 28259610 Free article. Clinical Trial.
Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction.
Sharp A, Cornforth C, Jackson R, Harrold J, Turner MA, Kenny L, Baker PN, Johnstone ED, Khalil A, von Dadelszen P, Papageorghiou AT, Alfirevic Z. Sharp A, et al. Among authors: jackson r. Lancet Child Adolesc Health. 2019 Mar;3(3):e2-e3. doi: 10.1016/S2352-4642(19)30020-3. Epub 2019 Jan 29. Lancet Child Adolesc Health. 2019. PMID: 30704877 No abstract available.
Effect of sildenafil on maternal hemodynamics in pregnancies complicated by severe early-onset fetal growth restriction: planned subgroup analysis from a multicenter randomized placebo-controlled double-blind trial.
Khalil A, Sharp A, Cornforth C, Jackson R, Mousa H, Stock S, Harrold J, Turner MA, Kenny LC, Baker PN, Johnstone ED, Von Dadelszen P, Magee L, Papageorghiou AT, Alfirevic Z. Khalil A, et al. Among authors: jackson r. Ultrasound Obstet Gynecol. 2020 Feb;55(2):198-209. doi: 10.1002/uog.20851. Ultrasound Obstet Gynecol. 2020. PMID: 31432556 Free article. Clinical Trial.
A prediction model for short-term neonatal outcomes in severe early-onset fetal growth restriction.
Sharp A, Jackson R, Cornforth C, Harrold J, Turner MA, Kenny L, Baker PN, Johnstone ED, Khalil A, von Dadelszen P, Papageorghiou AT, Alfirevic Z. Sharp A, et al. Among authors: jackson r. Eur J Obstet Gynecol Reprod Biol. 2019 Oct;241:109-118. doi: 10.1016/j.ejogrb.2019.08.007. Epub 2019 Aug 16. Eur J Obstet Gynecol Reprod Biol. 2019. PMID: 31499415 Clinical Trial.
The PLANES study: a protocol for a randomised controlled feasibility study of the placental growth factor (PlGF) blood test-informed care versus standard care alone for women with a small for gestational age fetus at or after 32 + 0 weeks' gestation.
Gent J, Bullough S, Harrold J, Jackson R, Woolfall K, Andronis L, Kenny L, Cornforth C, Heazell AEP, Benbow E, Alfirevic Z, Sharp A. Gent J, et al. Among authors: jackson r. Pilot Feasibility Stud. 2020 Nov 19;6(1):179. doi: 10.1186/s40814-020-00722-x. Pilot Feasibility Stud. 2020. PMID: 33292754 Free PMC article.
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.
Hussain SA, Lester JF, Jackson R, Gornall M, Qureshi M, Elliott A, Crabb SJ, Huddart RA, Vasudev N, Birtle AJ, Worlding J, James ND, Parikh O, Vilarino-Varela M, Alonzi R, Linch MD, Riaz IB, Catto JWF, Powles T, Jones RJ. Hussain SA, et al. Among authors: jackson r. Lancet Oncol. 2022 May;23(5):650-658. doi: 10.1016/S1470-2045(22)00158-9. Epub 2022 Apr 11. Lancet Oncol. 2022. PMID: 35421369 Free article. Clinical Trial.
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW; European Study Group for Pancreatic Cancer. Neoptolemos JP, et al. Among authors: jackson r. Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25. Lancet. 2017. PMID: 28129987 Free article. Clinical Trial.
5,454 results